Time to Upadacitinib treatment response over 16 weeks for patients with atopic dermatitis from Phase 2b randomized, placebo-controlled trial

被引:0
|
作者
Reich, Kristian [1 ]
Guttman-Yassky, Emma [2 ]
Hu, Xiaofei [3 ]
Calimlim, Brian [3 ]
Teixeira, Henrique [3 ]
de Bruin-Weller, Marjolein [4 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Skinflammat Ctr, Hamburg, Germany
[2] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY 10029 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Univ Med Ctr, Utrecht, Netherlands
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P032
引用
收藏
页码:18 / 19
页数:2
相关论文
共 50 条
  • [1] Early response to upadacitinib in moderate-to-severe atopic dermatitis: Results from a phase 2b randomized, placebo-controlled trial
    Reich, K.
    Guttman-Yassky, E.
    Beck, L. A.
    Hu, X.
    Pangan, A. L.
    Teixeira, H. D.
    [J]. ALLERGY, 2018, 73 : 76 - 76
  • [2] UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Beck, L.
    Hong, C.
    Hu, X.
    Chen, S.
    Calimlim, B.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S21 - S21
  • [3] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Beck, Lisa A.
    Anderson, Jaclyn K.
    Hu, Xiaofei
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB294 - AB294
  • [4] The patient-reported burden of atopic dermatitis and its association with itch: Observations from the upadacitinib phase 2b randomized, placebo-controlled trial in moderate to severe atopic dermatitis
    Silverberg, Jonathan I.
    Calimlim, Brian
    Teixeira, Henrique D.
    Wu, Meijing
    Simpson, Eric L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB77 - AB77
  • [5] Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial
    Hong, C. -H.
    Wu, T.
    Calimlim, B.
    Teixeira, H.
    de Bruin-Weller, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 10 - 10
  • [6] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
  • [7] Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    Guttman-Yassky, Emma
    Thaci, Diamant
    Pangan, Aileen L.
    Hong, H. Chih-ho
    Papp, Kim A.
    Reich, Kristian
    Beck, Lisa A.
    Mohamed, Mohamed-Eslam F.
    Othman, Ahmed A.
    Anderson, Jaclyn K.
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (03) : 877 - 884
  • [8] Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase IIb randomized, placebo-controlled trial
    De Bruin-Weller, M. S.
    Guttman-Yassky, E.
    Forman, S. B.
    Bodhani, A.
    Chen, S.
    Pangan, A. L.
    Teixeira, H. D.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E13 - E13
  • [9] Achieving an itch-free state with Upadacitinib: a post-hoc analysis of data from the Phase 2b randomized, doubleblind, placebo-controlled trial in moderate-to-severe atopic dermatitis
    Silverberg, J.
    Reich, K.
    Calimlim, B., III
    Gu, Y.
    Hu, X.
    Teixera, H.
    Guttman-Yassky, E.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 37 - 37
  • [10] UPADACITINIB IN ADULT ATOPIC DERMATITIS: LOSS OF ITCH EFFICACY AFTER TREATMENT WITHDRAWAL IN A PHASE 2B TRIAL
    Staender, Sonja
    Kim, Brian
    Beck, Lisa A.
    Teixeira, Henrique D.
    Wu, Meijing
    Calimlim, Brian M.
    Thyssen, Jacob P.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 60 - 61